Ingrid Stuiver, Ph.D.

Dr. Stuiver is responsible for leading and executing the LJI translational research strategies by maintaining a deep engagement with the LJI discovery research teams and providing advice on potential preclinical and translational pathways with the final goal being commercial development. She ensures that the preclinical and development studies are rigorous and structured in preparation to secure solid intellectual property and for potential IND submissions. Dr. Stuiver also liaises between departments to ensure external fundraising exposure of those projects entering the commercial track. Finally, she is integral to the institutes’ business development activities.

Dr. Stuiver’s background encompasses a wide breadth of research and development as well as clinical experience in academic, commercial and healthcare settings. She has worked on numerous disease modalities including metabolic, inflammatory and infectious diseases and cancer. She is also versed in the translation of academic research to a for-profit entity, process development, preclinical and clinical trial design, IND submissions and GMP preparation and has directed and confirmed compliance of clinical CROs, core laboratories and GMP facilities and ensured that clinical research deliverables were received on time in the US and EU. In addition, Dr. Stuiver has worked with a number of for profit entities as VP of Clinical Operations and in that capacity overseen, developed and written the documentation needed for a number of successful FDA submissions. Finally, Dr. Stuiver has raised over $65 MM in grant funding and incentives for her research and other non- or for-profit entities.

Dr. Stuiver received her BA in Cell Biology and Biochemistry from the University of California, San Diego and her Ph.D. in Molecular and Cell Biology, Minor in Biochemistry from the University of Arizona, Tucson, AZ. She is also certified in Management, Biostatistics and ADMET.